Docetaxel, carboplatin, and trastuzumab (TCH) preoperative induction treatment (IRx) in patients (pts) with HER2-positive breast cancer (BC).

Docetaxel, Carboplatin, and Trastuzumab (TCH) for HER2-Positive Breast Cancer

“…The docetaxel, carboplatin, and trastuzumab regimen (see Table 1 ) has been studied as treatment for HER2-positive advanced breast cancer and adjuvant or neoadjuvant therapy in operable HER2-positive breast cancer. 1–7 Current guidelines include TCH as one of the regimens recommended for neoadjuvant or adjuvant therapy of operable HER2-positive invasive breast cancer and for therapy of recurrent or metastatic HER2-positive invasive breast cancer. 8…”